The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

The purpose of the study is to see how this treatment affects the cancer at the biological level. The study will give the medicines over repeated treatment cycles and follow how the cancer and body change over time. Samples and scans may be collected during the study to learn more about the cancer, and the treatment will be watched for side effects and other safety issues.

Prifetrastat (PF-07248144) is a new medicine that blocks a protein called KAT6, which may help slow cancer growth. ctDNA is small pieces of cancer-related DNA found in the blood, and the study will look at changes in this material to better understand the treatment’s effect. The study also includes analysis of cancer tissue and blood to learn more about how the medicines work.

The purpose of the study is to assess how safe the investigational drug is and to determine the appropriate dose when used alone or in combination with the hormone therapies.

Participants will first undergo screening tests, then begin taking the study medication in a series of visits. Depending on the study arm, they may receive an injection of the hormone blocker, a daily pill, or both, alongside the oral investigational drug. Throughout the study they will have regular check‑ups that include blood work, vital‑sign measurements, and heart rhythm checks to monitor safety. Treatment continues until the cancer shows growth, side effects become unacceptable, or the study ends.

Participants in the study will receive the treatment orally in the form of film-coated tablets. The study will last for a period of up to 52 weeks. During this time, the effects of the treatment will be monitored to assess how well it works in controlling the cancer and to evaluate any side effects. The study will also look into how the treatment impacts the quality of life of the participants and will gather information on how the body processes the medication.

The trial aims to provide valuable insights into the potential benefits of combining fulvestrant and alpelisib for treating this specific type of breast cancer. It will also help in understanding the management of side effects, such as alpelisib-induced hyperglycemia, which is an increase in blood sugar levels. The study will contribute to the knowledge of how these medications can be used effectively in patients with the PIK3CA mutation.

The purpose of this study is to find out if treatment with ribociclib and hormone therapy alone works as well as treatment that includes chemotherapy followed by ribociclib and hormone therapy in preventing breast cancer from returning. The study will look at how long patients remain free from invasive breast cancer coming back, including cancer returning in the same breast, nearby areas, the opposite breast, spreading to other parts of the body, or death from any cause. The study will also examine other outcomes such as survival without distant disease spread, overall survival, and what types of cancer recurrence occur.

Patients in the study will have already had surgery to remove their breast cancer with clear margins. They will be randomly assigned to one of the two treatment groups. Treatment with ribociclib will be given for a specific period, and hormone therapy is planned to continue for at least five years. Throughout the study, patients will be monitored for side effects and their quality of life will be assessed using questionnaires. Regular blood tests and heart monitoring will be performed to check for any problems related to the treatment. The study will follow patients over several years to compare how well each treatment approach works in preventing the cancer from returning.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The study will use several medications including paclitaxel, docetaxel, epirubicin, doxorubicin, and cyclophosphamide as chemotherapy options. For hormone therapy, the treatments include tamoxifen, anastrozole, letrozole, exemestane, and hormone-suppressing medications like goserelin, triptorelin, and leuprorelin.

The treatment approach will be personalized based on the results of the gene expression test. Patients will receive either standard chemotherapy followed by hormone therapy, or hormone therapy alone, depending on their test results. The study will monitor patients for many years to compare the effectiveness of these treatment approaches in preventing cancer recurrence and ensuring long-term survival.

The purpose of this research is to evaluate how well the combination of elacestrant and exemestane works in treating this specific type of breast cancer. The study will include patients whose cancer has previously been treated with other therapies but has continued to grow or spread. During the study, patients will receive both medications and undergo various medical examinations to monitor their health and the effectiveness of the treatment.

This is a phase 2 clinical trial, which means it aims to gather more information about how well this combination treatment works. The treatment period may last up to 6 months, during which patients will take their medications daily. Throughout the study, doctors will closely monitor patients’ health and any side effects that may occur.

The purpose of this research is to determine how well patritumab deruxtecan works compared to standard treatments in controlling the disease and helping patients live longer. The study is designed for patients whose cancer has continued to grow despite previous treatment with hormone therapy and special medications called CDK4/6 inhibitors.

During the study, participants will be randomly assigned to receive either patritumab deruxtecan or one of the standard treatment options. All medications will be given through an intravenous infusion (directly into a vein), except for capecitabine which is taken as tablets by mouth. The treatment will continue as long as it is helping the patient and side effects are manageable.

In this trial, participants will be monitored to see how long they remain free from the cancer returning. The medications typically used in such treatments include Exemestane, Anastrozole, Letrozole, and Tamoxifen. These drugs are taken orally to prevent the cancer from growing back by interfering with the body’s hormone levels. During the course of the study, researchers will observe the participants over several years to track their health and monitor for any signs of the disease returning in the breast or in other parts of the body.

The purpose of this study is to find out if ECI830 is safe when given alone or with other treatments, to determine the right dose to use, and to see if the combination of ECI830 with ribociclib and fulvestrant can help stop the cancer from getting worse in patients with HR-positive HER2-negative breast cancer who have already received treatment with a type of medicine called a CDK4/6 inhibitor. The study will also look at how well these treatments work against the cancer by measuring things like whether tumors shrink or stop growing.

The study has two parts. The first part will test different doses of ECI830 to see what side effects occur and to find the best dose to use. The second part will give the chosen dose of ECI830 in combination with ribociclib and fulvestrant to a larger group of patients with breast cancer to see how well this combination works. During the study, patients will have regular check-ups where doctors will monitor their health, take blood samples, check heart activity, and use imaging scans to see how the cancer is responding to treatment. The study will track how long patients live without their cancer getting worse and how long they survive overall.

The treatment will involve taking PF-07248144 tablets by mouth along with fulvestrant injections into the muscle. Some patients will receive this combination, while others will receive different standard treatments such as everolimus or exemestane. The purpose is to determine if the combination of PF-07248144 and fulvestrant works better than currently available treatments in stopping the cancer from growing.

The study will last for up to 24 months. During this time, patients will have regular check-ups to monitor their health and see how well the treatment is working. Doctors will use special scans to measure if tumors are shrinking, staying the same size, or growing. They will also keep track of any side effects that patients may experience during the treatment.

The purpose of this research is to evaluate how patient education and personalized coaching affect how long patients continue their treatment with ribociclib. The study will examine different approaches to supporting patients through their treatment journey and measure how these approaches impact treatment continuation.

During the study, participants will take ribociclib tablets daily and receive specialized coaching support. Throughout the treatment period, which lasts up to 36 months, patients will complete questionnaires about their quality of life and overall well-being. They will also keep a diary to track any breaks in their treatment. The study will monitor how patients manage their treatment and any side effects that may occur.

Patients in this study will receive both the medication Elacestrant and PULSAR radiotherapy before undergoing surgery to remove the tumor. During the study, doctors will monitor for side effects and evaluate how well the treatment works by examining the breast tissue and lymph nodes removed during surgery. They will look for the absence of cancer cells, which is called a pathological complete response, or measure any remaining cancer using the residual cancer burden assessment.

The study will also track patients’ outcomes over time, including whether the cancer returns, how long patients remain free of invasive disease, and overall survival. Additionally, researchers will analyze tissue and blood samples to better understand how the treatment affects the cancer at a cellular level.

The study involves patients taking the medications before their planned surgery. During this time, researchers will use various imaging techniques such as magnetic resonance imaging (MRI) and ultrasonography to examine the tumor. After surgery, the removed tumor tissue will be analyzed using mass spectrometry to measure the concentration of medications in different areas of the tumor.

Additionally, researchers will examine how the medications affect the immune system by studying immune cells in both the sentinel lymph node (the first lymph node to which cancer cells are likely to spread) and in the blood. They will also assess how effectively the medications work against the cancer by measuring changes in the tumor and specific markers of cell growth.

Participants in the study will receive treatment over a period of up to 36 months. The study will monitor the participants’ health and the progression of their breast cancer during this time. The goal is to evaluate the rate of invasive breast cancer-free survival at three years for those taking ribociclib with endocrine therapy. This means the study will look at how many participants remain free from invasive breast cancer after three years of treatment. The study will also track any side effects or adverse events that participants may experience while taking the medication.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on the effectiveness of the treatment. The study aims to provide valuable insights into the potential benefits of using ribociclib in combination with endocrine therapy for treating early-stage HR-positive HER2-negative breast cancer. This research could help improve treatment options and outcomes for patients with this type of breast cancer in the future.

Participants in the study will receive the treatment and be monitored over a period of time to observe any changes in their condition. The study aims to measure the response of the cancer to the treatment, looking for signs of improvement or stability. The treatment will be given in cycles, and the health of the participants will be closely watched by the study team to ensure safety and to gather information on how the treatment affects the cancer.

The study will also collect data on any side effects experienced by participants, as well as other health indicators such as laboratory test results and vital signs. This information will help researchers understand the overall impact of zelenectide pevedotin on patients with NECTIN4 Amplified Advanced Breast Cancer and contribute to the development of new treatment options for this disease.

The purpose of this study is to evaluate the safety and effectiveness of the combination of capivasertib and fulvestrant in patients whose cancer has progressed despite previous hormone-based treatments. Participants in the study will receive these medications and will be monitored to assess how long they can continue the treatment before needing to switch to another therapy. The study will also look at how this treatment affects the quality of life of the participants.

Throughout the study, participants will take the medications orally and will be regularly assessed by healthcare professionals. The study aims to provide insights into how well this combination of treatments works in managing advanced breast cancer and improving the time patients can stay on treatment. The trial will also explore the impact of the treatment on patients’ daily lives and overall well-being.

The purpose of the study is to evaluate which treatment combination is more effective as a neoadjuvant therapy, meaning it is given before the main treatment, usually surgery, to shrink the tumor. Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of six months, during which participants will take the medications orally. The effectiveness of the treatments will be assessed at the time of surgery, using a measure called the modified PEPI score, which helps to evaluate the response of the cancer to the treatment.

This trial aims to provide valuable information on the best treatment approach for patients with endocrine-responsive HER2-negative early breast cancer. By comparing the two treatment combinations, researchers hope to determine which is more effective in reducing the size of the tumor and improving outcomes for patients. The study will also look at other factors, such as changes in tumor size and the proportion of tumors that respond to the treatment, to gain a comprehensive understanding of the benefits of each treatment option.

The purpose of the study is to evaluate the safety and effectiveness of these treatments when given in different sequences. Participants will receive these medications through intravenous infusion, which means the medicine is given directly into a vein, or orally, which means the medicine is taken by mouth. The study will compare the effects of these treatments when given before or after surgery, as well as their impact on the cancer’s response to treatment.

Throughout the study, participants will be monitored for any side effects and the overall response of their cancer to the treatment. The study aims to determine the best treatment sequence to improve outcomes for patients with these specific types of breast cancer. The trial will continue for several years to gather comprehensive data on the effectiveness and safety of the treatments being tested.

The purpose of the study is to see how well Elacestrant works compared to these standard treatments in preventing the return of breast cancer. Participants in the study will be randomly assigned to receive either Elacestrant or one of the standard hormone therapies. The study will last for a period of up to 60 months, during which participants will take their assigned medication daily. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition.

The study will also look at how the treatments affect the participants’ quality of life, including any side effects they may experience. This will help researchers understand the overall impact of Elacestrant compared to the standard treatments. The information gathered from this study will contribute to better understanding and potentially improving treatment options for people with this type of breast cancer.

The purpose of the study is to determine if either duloxetine or furosemide can better control these types of pain over a period of three months. Participants will be randomly assigned to receive one of these medications or a placebo. The study will last for up to six months, during which participants will take the medication orally. The trial aims to assess changes in pain levels and overall quality of life using specific questionnaires designed to measure these aspects.

Throughout the study, participants will be monitored for any changes in their symptoms and overall health. The trial will also evaluate the safety of the medications by tracking any side effects or adverse events. The ultimate goal is to find supportive treatments that can help patients manage the side effects of their cancer therapy, thereby improving their quality of life during treatment.

The purpose of the study is to evaluate if there are differences in the occurrence of high blood sugar levels, known as hyperglycemia, when alpelisib is taken at night with a fasting period and a low carbohydrate diet, compared to taking it as usually recommended. The study will observe participants over a period of three months or until 30 days after they stop the treatment. Participants will be men and postmenopausal women who have a mutation in the PIK3CA gene and have experienced progression of their cancer after previous hormone therapy.

During the study, participants will be randomly assigned to different groups to receive the treatment at different times and under different dietary conditions. The study will monitor the incidence of severe hyperglycemia and other related outcomes. The goal is to determine the best way to administer alpelisib to minimize side effects and improve its effectiveness in treating this type of breast cancer.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

Participants in the study will be randomly assigned to receive either the combination of elacestrant and everolimus, elacestrant with a placebo, or another treatment as part of the study. The study will be conducted in a way that neither the participants nor the researchers know which treatment each participant is receiving, a method known as “double-blind.” This helps ensure that the results are not influenced by expectations about the treatment. The main goal is to see if the combination of elacestrant and everolimus can help patients live longer without their cancer getting worse, which is referred to as “progression-free survival.”

The study will take place over several years, with regular check-ups and assessments to monitor the participants’ health and the progression of their cancer. Participants will receive their assigned treatment for a set period, and their response to the treatment will be closely monitored through various tests and evaluations. The study will also look at the overall survival of participants, the response of the cancer to the treatment, and any side effects experienced. This research is important for understanding how to better treat this specific type of breast cancer and improve outcomes for patients in the future.

The purpose of the study is to compare how well these treatment combinations work in controlling the cancer. Participants in the study will be randomly assigned to one of two groups. One group will receive abemaciclib combined with either letrozole or fulvestrant, while the other group will receive paclitaxel. The study will last for up to 12 months, during which time the participants will receive their assigned treatments and be monitored regularly. The researchers will assess the response of the cancer to the treatments at various points throughout the study.

This trial aims to provide valuable information on the best treatment approach for patients with this specific type of breast cancer. By comparing the different treatment combinations, the study hopes to identify which option offers the most benefit in terms of controlling the disease and improving patient outcomes. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather important data on the effectiveness of the treatments.

The purpose of the study is to evaluate how well the 68Ga-ABS011 PET/CT works compared to the standard tests currently used to check the status of a protein called HER2 in breast cancer. During the study, participants will receive an injection of 68Ga-ABS011, and then undergo a PET/CT scan. This will help doctors determine if the new method provides better or additional information compared to the usual tests. The study will also monitor any side effects that participants might experience from the injection or the scan.

Participants in the study will have several visits over a period of time, during which they will undergo the PET/CT scan and possibly a biopsy, which is a procedure to take a small sample of tissue for testing. The study aims to see if the new imaging method can help guide treatment decisions and improve the management of metastatic breast cancer. The trial is expected to continue until the end of 2025.

The purpose of the study is to compare the safety and effectiveness of niraparib with a placebo. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will monitor the safety of niraparib by observing any side effects or changes in health status. The trial will also explore how well the medication works in preventing the return of cancer.

Participants will take the medication in the form of tablets by mouth. The study will last for a period of time, during which regular check-ups and tests will be conducted to ensure the safety and well-being of the participants. The results of this study will help determine if niraparib is a safe and effective treatment option for these specific types of breast cancer.

The medication being tested, everolimus, is taken as tablets by mouth along with regular hormone therapy. Some participants will receive everolimus tablets while others will receive placebo tablets. The treatment continues for 2 years, during which time participants take their assigned medication in addition to their standard hormone therapy.

The main goal of this research is to determine if adding everolimus to standard hormone treatment helps keep patients cancer-free for a longer time. Throughout the study, doctors will monitor participants’ health and track whether the cancer returns. The study will also look at how well patients tolerate the treatment combination and its effects on their overall health.

The purpose of this study is to evaluate how well the combination of Abemaciclib and endocrine therapy works in managing the cancer and to focus on managing side effects using digital tools. Participants will be divided into two groups based on their previous treatment history. The study will monitor the time it takes for the cancer to progress or for the patient to pass away, which is known as progression-free survival. This will help researchers understand the effectiveness of the treatment. The study will also look at overall survival, which is the length of time patients live after starting the treatment, and the objective response rate, which measures how much the cancer shrinks or disappears after treatment.

Participants in the study will take the medications for a period of up to 36 months. The study will involve regular check-ups and assessments to monitor the cancer’s response to the treatment and any side effects experienced. The use of a digital health application is encouraged to help report side effects and other outcomes during the study. This trial aims to provide valuable information on the effectiveness and safety of combining Abemaciclib with endocrine therapy in treating hormone receptor-positive HER2-negative breast cancer.

Participants in the study will receive either ribociclib or palbociclib, along with standard endocrine therapy. Ribociclib is taken as a film-coated tablet, while palbociclib is available in hard capsule form. The study will also include a group receiving a placebo. The trial will monitor the participants over a period to assess how well the treatments work in controlling the cancer and improving the quality of life for patients.

The study will involve regular visits to the clinic for treatment and monitoring. Participants will undergo various tests to track the progress of their condition and the effects of the treatment. The trial aims to provide valuable information on the safety and effectiveness of these medications in treating this specific type of breast cancer.

The purpose of the study is to evaluate how well Trastuzumab Deruxtecan works compared to the other chemotherapy treatments. Participants will receive either Trastuzumab Deruxtecan or a chemotherapy treatment selected by their doctor. The chemotherapy options may include medications such as Paclitaxel, Abraxane (a form of paclitaxel), or Capecitabine. These treatments are given through an infusion, which means they are administered directly into the bloodstream through a vein, or taken orally in the case of Capecitabine.

The study will monitor participants over a period of time to observe the effects of the treatments on their cancer. The main focus will be on how long the cancer stays under control and the overall survival of the participants. The study will also look at the safety and side effects of Trastuzumab Deruxtecan compared to the other chemotherapy treatments. Participants will be closely monitored by their healthcare team throughout the study to ensure their safety and well-being.

The purpose of the study is to see how effective these treatments are for patients with this specific type of breast cancer. The study is divided into two groups. In one group, patients will receive MEN1611 alone, and in the other group, patients will receive MEN1611 together with eribulin. The study will monitor how the cancer responds to these treatments over a period of time.

Participants in the study will receive the treatment and be regularly monitored by healthcare professionals. The study will track the progress of the cancer and any changes in the patient’s condition. The goal is to determine if these treatments can help control the cancer and improve the patient’s quality of life. The study will also look at any side effects that may occur during the treatment period.

Participants in the study will take part in a treatment period that can last up to 24 months. During this time, they will receive either the combination of endocrine therapy and ribociclib or chemotherapy. The study aims to observe the participants over a period of time to see how well the treatments work in preventing the cancer from coming back and to monitor the overall health and quality of life of the participants.

The study will also look at how well participants adhere to their treatment plans, which means how consistently they take their medication as prescribed. Additionally, researchers will collect information on the participants’ response to treatment, including any changes in the size of the tumor and the rate of breast-conserving surgeries. The ultimate goal is to find the most effective treatment option for patients with HR-positive/HER2-negative early breast cancer, improving their chances of living without the disease returning.

The purpose of the study is to find the best dose of Alisertib when used with hormone therapy, ensuring it is both safe and effective for future use. The study will involve several medications, including Letrozole, Tamoxifen, Anastrozole, Exemestane, and Fulvestrant. These medications are commonly used in hormone therapy to treat breast cancer. Participants in the study will receive one of these medications along with Alisertib or a placebo. The study will last for a period of 28 days, during which the effects of the treatment will be closely monitored.

Throughout the study, participants will be observed for any side effects or changes in their condition. The study aims to gather information on how well the combination of Alisertib and hormone therapy works in controlling the cancer and improving the participants’ health. This information will help determine the potential of this treatment combination for future use in patients with HR+, HER2-negative breast cancer.

The purpose of the study is to evaluate the long-term effectiveness of this treatment combination in patients with this specific type of breast cancer. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study aims to determine if this combination can help reduce the risk of the cancer returning and improve overall outcomes for patients.

Throughout the study, participants will take the medications orally and will be regularly monitored by healthcare professionals. The study will assess various outcomes, including the time it takes for the cancer to return and the overall survival of the participants. The trial will also look at the safety of the treatment and any side effects that may occur. This research is important for understanding how to better treat this type of breast cancer and improve the quality of life for those affected by it.

The main purpose is to determine which treatment sequence works better: using a CDK4/6 inhibitor with hormone therapy first, followed by fulvestrant alone when the disease progresses; or starting with hormone therapy alone, followed by fulvestrant combined with a CDK4/6 inhibitor when the disease progresses. Additional hormone therapies that may be used include anastrozole, letrozole, goserelin, and leuprorelin.

During the study, patients will receive treatment until their disease progresses or they cannot tolerate the medication. The researchers will monitor how long it takes for the cancer to progress after both first and second treatments, overall survival, quality of life, and side effects. They will also collect tumor samples and blood tests to study markers that might help predict which patients respond best to treatment.

The study is divided into two parts. In the first part, researchers will determine the best dose of EP0062 when used by itself. In the second part, they will explore how EP0062 works when combined with other standard treatments for breast cancer. The goal is to find the most effective and safe way to use EP0062 for patients with AR-positive, HER2-negative, and ER-positive breast cancer. These terms refer to specific characteristics of the cancer cells that can influence how the cancer behaves and responds to treatment.

Throughout the study, participants will be closely monitored for any side effects and how their cancer responds to the treatment. The trial will help determine the optimal dose of EP0062 and assess its potential benefits for patients with advanced breast cancer. This research is important for developing new treatment options for individuals with this type of cancer.

Participants in the study will receive AZD8421 in the form of a film-coated tablet, taken orally. Some participants may also receive other medications, such as Palbociclib, Abemaciclib, Ribociclib, or Zoladex, which are also used to treat cancer. The study will monitor how the body processes these medications and will look for any side effects or changes in health. The study will also include a placebo group to compare the effects of the medications.

The trial will take place over a period of time, during which participants will have regular check-ups and tests to monitor their health and the effects of the treatment. These tests may include imaging scans like MRI or CT scans to assess the size and progression of tumors. The study aims to gather important information that could help improve treatment options for people with these types of cancer in the future.

The purpose of the study is to evaluate how well DB-1303 works in slowing down the progression of the cancer compared to the usual chemotherapy treatments. Participants in the study will be randomly assigned to receive either DB-1303 or one of the standard chemotherapy drugs, which may include Capecitabine, Paclitaxel, or Paclitaxel Albumin-Bound. These chemotherapy drugs are commonly used to treat breast cancer and are administered either orally or through intravenous infusion, depending on the specific medication.

The study will take place over a period of time, during which participants will receive their assigned treatment and be monitored for any changes in their condition. The goal is to determine which treatment is more effective in extending the time before the cancer progresses. Participants will also be observed for any side effects or changes in their overall health. This study aims to provide valuable information that could help improve treatment options for patients with this specific type of breast cancer.